WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005108429) NOVEL SOLUBLE CD14 ANTIGEN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/108429    International Application No.:    PCT/JP2005/008635
Publication Date: 17.11.2005 International Filing Date: 11.05.2005
IPC:
C07K 14/705 (2006.01), C12P 21/02 (2006.01), G01N 33/53 (2006.01), G01N 33/531 (2006.01)
Applicants: MOCHIDA PHARMACEUTICAL CO., LTD. [JP/JP]; 7, Yotsuya 1-chome, Shinjuku-ku, Tokyo 1608515 (JP) (For All Designated States Except US).
FURUSAKO, Shoji [JP/JP]; (JP) (For US Only).
SHIRAKAWA, Kamon [JP/JP]; (JP) (For US Only).
HIROSE, Jiro [JP/JP]; (JP) (For US Only)
Inventors: FURUSAKO, Shoji; (JP).
SHIRAKAWA, Kamon; (JP).
HIROSE, Jiro; (JP)
Agent: WATANABE, Mochitoshi; Hayakawa-tonakai Bldg. 3F 12-5, Iwamoto-cho 2-chome Chiyoda-ku, Tokyo 1010032 (JP)
Priority Data:
2004-141600 11.05.2004 JP
Title (EN) NOVEL SOLUBLE CD14 ANTIGEN
(FR) NOUVEL ANTIGÈNE CD14 SOLUBLE
(JA) 新規可溶性CD14抗原
Abstract: front page image
(EN)It is intended to provide a soluble CD14 antigen having the following properties 1) to 3), which is a novel protein in vivo and useful as a diagnostic maker for sepsis, and a recombinant soluble CD fragment: 1) having a molecular weight of 13±2 kDa in SDS-PAGE under nonreducing conditions; 2) having the amino acid sequence of SEQ ID NO:1 as the N-terminal sequence; and 3) specifically binding to an antibody constructed by using a peptide having the 16 amino acid residues represented by SEQ ID NO:2 as an antigen.
(FR)L'intention est de fournir un antigène CD14 soluble ayant les propriétés 1) à 3) suivantes, lequel est une nouvelle protéine in vivo et est utile comme marqueur de diagnostic pour la sepsie, et un fragment de CD soluble recombiné : 1) ayant un poids moléculaire de 13 ± 2 kDa mesuré par SDS-PAGE dans des conditions non réductrices ; 2) ayant la séquence d'acides aminés de la SEQ ID n° : 1 comme séquence en extrémité N ; et 3) liant spécifiquement un anticorps construit en utilisant un peptide ayant les 16 résidus d'acides aminés représentés par la SEQ ID n° : 2 en tant qu'antigène.
(JA) 生体内の新規な蛋白質であり、敗血症の診断マーカーとして有用な下記1)~3)の性質を有する可溶型CD14抗原、組換え型可溶性CDフラグメントを提供する。  1)非還元条件下SDS-PAGEでは、分子量13±2kDa、  2)N末端配列に配列番号1のアミノ酸配列を有する、及び  3)配列番号2に記載の16アミノ酸残基からなるペプチドを抗原として作製した抗体に特異的に結合する。
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)